Drugs / XW10508
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04966832 | Jul 2021 → Jun 2022 | — | XWPharma | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-08 | XWPharma | XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain xwpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XW10508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04966832 ↗ |
| Route | Oral | “ascending oral dose” NCT04966832 ↗ |